• Choosing Wisely
  • Swollen Joint Count: 44 joint homunculus
  • Disease Activity Score in 28 Joints
  • Rapid Access to Consultative Expertise (RACE)
  • 2010 ACR/EULAR Rheumatoid arthritis classification criteria
  • SF36 (Short‑Form Health Assessment Questionnaire)
  • Rheumatoid Arthritis (RA)
    • Swollen Joint Count: 44 joint homunculus
    • Disease Activity Score in 28 Joints
    • ACR Preliminary Definition of Improvement in RA
    • Clinical Disease Activity Index (CDAI)
    • Simplified Disease Activity Index (SDAI)
    • Disease Activity Score (DAS)
    • Health Assessment Questionnaire (HAQ)
    • Rheumatoid Arthritis Disease Activity Index (RADAI)
  • Psoriatic Arthritis (PsA)
    • Psoriatic Arthritis Disease Activity Score (PASDAS)
    • Psoriasis Area and Severity Index (PASI)
    • Dermatology Life Quality Index (DLQI)
  • Spondyloarthritis (SpA)
    • 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis
    • Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)
    • Bath Ankylosing Spondylitis Functional Index (BASFI)
    • Bath Ankylosing Spondylitis Metrology Index (BASMI)

  • Comprehensive Arthritis Referral Tool (CART)
  • ACR Referral Guidelines for Rheumatologist
  • Priority Referral Score

  • Patient Decision Aids: Arthritis
  • Getting a Grip Arthritis Prescription Pad
  • American College of Rheumatology (ACR)
    • 2012 Update of the 2008 Recommendations for the use of Disease‑Modifying Anti‑Rheumatic Drugs and Biologics in the treatment of Rheumatoid Arthritis
  • EULAR evidence‑based and consensus‑based recommendations on the management of medium to high‑dose glucocorticoid therapy in rheumatic diseases
  • EULAR evidence‑based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases
  • EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases
  • EULAR evidence‑based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis
  • Treat to target recommendations
  • Treat to target algorithm
  • Rheumatoid Arthritis (RA)
    • 2011/2012 CRA Treatment Recommendations for RA
    • 2011/2012 CRA Safety Recommendations for RA
    • EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease‑modifying antirheumatic drugs
    • CRA Canadian Consensus Statement on Early Optimal Therapy in Early RA
    • EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis
  • Spondyloarthritis (SpA)
    • CRA/SPARCC Treatment Recommendations for Spondyloarthritis
    • 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis
  • Psoriatic Arthritis (PsA)
    • European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies
  • Osteoporosis (OP)
    • American College of Rheumatology 2010 Recommendations for the Prevention and Treatment of Glucocorticoid‑Induced Osteoporosis
    • Clinician’s Guide to the American College of Rheumatology 2010 Recommendations for the Prevention and Treatment of Glucocorticoid‑Induced Osteoporosis

  • Patient Decision Aids: Arthritis
  • Advanced Clinician Practitioner in Arthritis Care (ACPAC) Program
  • FLARE questionnaire
  • RA follow‑up assessment checklist
  • Symptom Assessor Resource Tool
    • Rheumatoid Arthritis
    • Ankylosing Spondylitis
    • Psoriatic Arthritis
  • ACR Preliminary Definition of Improvement in RA
  • Ankylosing Spondylitis Disease Activity Score (ASDAS)
  • Ankylosing Spondylitis Quality of Life Questionnaire
  • American College of Rheumatology (ACR)
    • 2012 Update of the 2008 Recommendations for the use of Disease‑Modifying Anti‑Rheumatic Drugs and Biologics in the treatment of Rheumatoid Arthritis
  • EULAR evidence‑based and consensus‑based recommendations on the management of medium to high‑dose glucocorticoid therapy in rheumatic diseases
  • EULAR evidence‑based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases
  • EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases
  • EULAR evidence‑based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis
  • Treat to target recommendations
  • Treat to target algorithm
  • Rheumatoid Arthritis (RA)
    • 2011/2012 CRA Treatment Recommendations for RA
    • 2011/2012 CRA Safety Recommendations for RA
    • EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease‑modifying antirheumatic drugs
    • CRA Canadian Consensus Statement on Early Optimal Therapy in Early RA
    • EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis
  • Spondyloarthritis (SpA)
    • CRA/SPARCC Treatment Recommendations for Spondyloarthritis
    • 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis
  • Psoriatic Arthritis (PsA)
    • European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies
  • Osteoporosis (OP)
    • American College of Rheumatology 2010 Recommendations for the Prevention and Treatment of Glucocorticoid‑Induced Osteoporosis
    • Clinician’s Guide to the American College of Rheumatology 2010 Recommendations for the Prevention and Treatment of Glucocorticoid‑Induced Osteoporosis

  • Symptom Assessor Resource Tool
    • Rheumatoid Arthritis
    • Ankylosing Spondylitis
    • Psoriatic Arthritis
  • ACR Preliminary Definition of Improvement in RA
  • Ankylosing Spondylitis Disease Activity Score (ASDAS)
  • Ankylosing Spondylitis Quality of Life Questionnaire
  • American College of Rheumatology (ACR)
    • 2012 Update of the 2008 Recommendations for the use of Disease‑Modifying Anti‑Rheumatic Drugs and Biologics in the treatment of Rheumatoid Arthritis
  • EULAR evidence‑based and consensus‑based recommendations on the management of medium to high‑dose glucocorticoid therapy in rheumatic diseases
  • EULAR evidence‑based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases
  • EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases
  • EULAR evidence‑based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis
  • Treat to target recommendations
  • Treat to target algorithm
  • Rheumatoid Arthritis (RA)
    • 2011/2012 CRA Treatment Recommendations for RA
    • 2011/2012 CRA Safety Recommendations for RA
    • EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease‑modifying antirheumatic drugs
    • CRA Canadian Consensus Statement on Early Optimal Therapy in Early RA
    • EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis
  • Spondyloarthritis (SpA)
    • CRA/SPARCC Treatment Recommendations for Spondyloarthritis
    • 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis
  • Psoriatic Arthritis (PsA)
    • European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies
  • Osteoporosis (OP)
    • American College of Rheumatology 2010 Recommendations for the Prevention and Treatment of Glucocorticoid‑Induced Osteoporosis
    • Clinician’s Guide to the American College of Rheumatology 2010 Recommendations for the Prevention and Treatment of Glucocorticoid‑Induced Osteoporosis

  • Symptom Assessor Resource Tool
    • Rheumatoid Arthritis
    • Ankylosing Spondylitis
    • Psoriatic Arthritis
  • ACR Preliminary Definition of Improvement in RA
  • Ankylosing Spondylitis Disease Activity Score (ASDAS)
  • Ankylosing Spondylitis Quality of Life Questionnaire
  • American College of Rheumatology (ACR)
    • 2012 Update of the 2008 Recommendations for the use of Disease‑Modifying Anti‑Rheumatic Drugs and Biologics in the treatment of Rheumatoid Arthritis
  • EULAR evidence‑based and consensus‑based recommendations on the management of medium to high‑dose glucocorticoid therapy in rheumatic diseases
  • EULAR evidence‑based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases
  • EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases
  • EULAR evidence‑based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis
  • Treat to target recommendations
  • Treat to target algorithm
  • Rheumatoid Arthritis (RA)
    • 2011/2012 CRA Treatment Recommendations for RA
    • 2011/2012 CRA Safety Recommendations for RA
    • EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease‑modifying antirheumatic drugs
    • CRA Canadian Consensus Statement on Early Optimal Therapy in Early RA
    • EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis
  • Spondyloarthritis (SpA)
    • CRA/SPARCC Treatment Recommendations for Spondyloarthritis
    • 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis
  • Psoriatic Arthritis (PsA)
    • European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies
  • Osteoporosis (OP)
    • American College of Rheumatology 2010 Recommendations for the Prevention and Treatment of Glucocorticoid‑Induced Osteoporosis
    • Clinician’s Guide to the American College of Rheumatology 2010 Recommendations for the Prevention and Treatment of Glucocorticoid‑Induced Osteoporosis